Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)
This study has been completed.
Sponsored by: Bausch & Lomb, Inc.
Information provided by: Bausch & Lomb, Inc.
ClinicalTrials.gov Identifier: NCT00347594
  Purpose

The purpose of this study is to measure the aberrations, corneal surface topography and pachymetry of normal human eyes with the NGDI.


Condition Intervention
Healthy
Device: NGDI

U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • +10.00D to -20.00D of absolute spherical ametropia
  • Must be part of the Bausch & Lomb research clinic
  • Snellen visual acuity must be correctable to 20/25

Exclusion Criteria:

  • No more than -6.00D of refractive astigmatism
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00347594

Locations
United States, New York
Bausch & Lomb
Rochester, New York, United States, 14609
Sponsors and Collaborators
Bausch & Lomb, Inc.
Investigators
Principal Investigator: Michelle Lagana Bausch & Lomb, Inc.
  More Information

Study ID Numbers: GVC2-03-052
Study First Received: June 30, 2006
Last Updated: November 27, 2007
ClinicalTrials.gov Identifier: NCT00347594  
Health Authority: United States: Institutional Review Board

Keywords provided by Bausch & Lomb, Inc.:
Corneal surface topography and ocular aberrations.

Study placed in the following topic categories:
Healthy

ClinicalTrials.gov processed this record on January 14, 2009